These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9873858)

  • 1. The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    Haemophilia; 1998 Jan; 4(1):4-9. PubMed ID: 9873858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive care for hemophilia and other inherited bleeding disorders.
    Page D
    Transfus Apher Sci; 2019 Oct; 58(5):565-568. PubMed ID: 31427262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
    Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
    Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
    van Galen KP; Engelen ET; Mauser-Bunschoten EP; van Es RJ; Schutgens RE
    Cochrane Database Syst Rev; 2015 Dec; (12):CD011385. PubMed ID: 26704192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress in the clinical management of haemophilia.
    Bloom AL
    Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
    [No Abstract]   [Full Text] [Related]  

  • 8. Blood and neoplastic diseases. Haemophilia and related disorders.
    Rizza CR
    Br Med J; 1974 Oct; 4(5935):36-8. PubMed ID: 4547674
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-of-illness study of severe haemophilia A and B in five French haemophilia treatment centres.
    Nerich V; Tissot E; Faradji A; Demesmay K; Bertrand MA; Lorenzini JL; Briquel ME; Pouzol P; Woronoff-Lemsi MC
    Pharm World Sci; 2008 Jun; 30(3):287-92. PubMed ID: 18085428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease.
    Miners AH; Sabin CA; Tolley KH; Lee CA
    J Intern Med; 1998 Dec; 244(6):515-22. PubMed ID: 9893105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A protocol for the dental management of von Willebrand's disease, haemophilia A and haemophilia B.
    Stubbs M; Lloyd J
    Aust Dent J; 2001 Mar; 46(1):37-40. PubMed ID: 11355239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
    Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
    Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical staff conference: Hemophilia and von Willebrand's disease. Fourth annual Paul M. Aggeler memorial lecture.
    West J Med; 1974 Mar; 120(3):226-32. PubMed ID: 4544608
    [No Abstract]   [Full Text] [Related]  

  • 14. [A new therapy of hemophilia with ranitidine].
    Hu LM; Ye LL; Xu B
    Zhonghua Nei Ke Za Zhi; 1990 Feb; 29(2):85-7, 125. PubMed ID: 2120016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From the Centers for Disease Control and Prevention. Hepatitis A among persons with hemophilia who received clotting factor concentrate--United States, September-December 1995.
    JAMA; 1996 Feb; 275(6):427-8. PubMed ID: 8627951
    [No Abstract]   [Full Text] [Related]  

  • 19. Non-thrombotic-, non-inhibitor-associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand's disease: a systematic review of prospective studies.
    Franchini M; Makris M; Santagostino E; Coppola A; Mannucci PM
    Haemophilia; 2012 May; 18(3):e164-72. PubMed ID: 22250981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(1):19-25. PubMed ID: 7796372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.